Firm Represents Simcere Pharmaceutical Group in its IPO on the New York Stock Exchange
04.26.07
This is only gets display when printing
The Hong Kong office of the Firm represented Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals in the fast growing China market, in connection with its initial public offering on the New York Stock Exchange of 15,625,000 American Depositary Shares, raising approximately US$260.5 million. The transaction is the largest IPO of a pharmaceutical company out of China. The global bookrunner for the offering was Goldman Sachs.
The Simpson Thacher team for the transaction included Leiming Chen, Shuang Zhao and David Lee (Corporate).